Nextech Invest
SlowingFiled to raiseSenningerberg, N4Biotech & pharma, Manufacturing & industrialsLast fund filed March 2026
2 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Equip Capital Fund III SCSp | March 2026 | Indefinite | $7.9M | 1 |
| Nextech VIII SCSP | October 2024 | Indefinite | $298M | 17 |
| Nextech VIII Carry SCSPFiled to raise in 2024, with no closing reported yet. | 2024 | Indefinite | $0 | 0 |
| Equip Capital Fund II SCSp | March 2023 | Indefinite | $24M | 1 |
| Nextech Crossover I Carry SCSp |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
12 partners are named across this firm’s filings, 2 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Thilo SchroederNot on the current fund | Slowing | Biotech & pharma | 8 |
Categories of Nextech Invest’s own portfolio companies, based on 14 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Nextech Invest’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| The Column Group | 3 | A2 Biotherapeutics, Circle Pharma, Hexagon Bio |
| Third Rock Ventures | 3 | Blueprint Medicines, IMAGINAB, Revolution Medicines |
| Vida Ventures | 3 | A2 Biotherapeutics, Alterome Therapeutics, IconOVir Bio |
| Curie Bio |
| March 2022 |
| Indefinite |
| $2,678 |
| 13 |
| Nextech VII Carry SCSp | March 2022 | Indefinite | $2,678 | 13 |
| Nextech VII Oncology SCSp | November 2021 | Indefinite | $247M | 95 |
| NEXTECH CROSSOVER I SCSP | November 2021 | Indefinite | $208M | 94 |
| HitecVision NEF Feeder SCSp | September 2021 | Indefinite | $78M | 5 |
| H.I.G. Infrastructure Partners C | July 2021 | Indefinite | $107M | 3 |
| NEXTECH VI ONCOLOGY SCSPFiled to raise in 2020, with no closing reported yet. | 2020 | Indefinite | $0 | 0 |
| 1 |
| Alfred ScheideggerNot on the current fund | Quiet | Biotech & pharma | 1 | 0 |
| Anthony TamerNot on the current fund | Quiet | None listed | 0 | 0 |
| Costas Constantinides | Quiet | None listed | 0 | 0 |
| Dalia BleyerNot on the current fund | Quiet | None listed | 0 | 0 |
| Ian Charoub | Quiet | None listed | 0 | 0 |
| Jacob LovenNot on the current fund | Quiet | None listed | 1 | 0 |
| Jakob LovenNot on the current fund | Quiet | Biotech & pharma | 6 | 0 |
| James PledgerNot on the current fund | Quiet | None listed | 0 | 0 |
| Richard SiegelNot on the current fund | Quiet | Manufacturing & industrials | 1 | 0 |
| Rocco SgobboNot on the current fund | Quiet | None listed | 0 | 0 |
| Sami MnaymnehNot on the current fund | Quiet | None listed | 0 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
| 2 |
| Blueprint Medicines, Revolution Medicines |
| U.S Venture Partners | 2 | Cleave Biosciences, Silverback Therapeutics |
| ARCH Venture Partners | 1 | Vividion Therapeutics |
| Excelerate Health Ventures | 1 | Cleave Biosciences |
| Venbio Global Strategic | 1 | Arrakis Therapeutics |
| Versant Venture Capital | 1 | Vividion Therapeutics |
A shared board seat: a company where filings name a Nextech Invest partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.